| Authors | Jo, H.E. Troy, L.K. Keir, G. Chambers, D.C. Holland, A. Goh, N. Wilsher, M. de Boer, S. Moodley, Y. Grainge, C. Whitford, H. Chapman, S. Reynolds, P.N. Glaspole, I. Beatson, D. Jones, L. Hopkins, P. Corte, T.J. |
|---|---|
| Type | Position Statement |
| Journal | Respirology |
| PubMed ID | 28845557 |
| Year of Publication | 2018 |
| URL | https://www.ncbi.nlm.nih.gov/pubmed/28845557 |
| DOI | /10.1111/resp.13146 |
| Download |  Jo_et_al-2017-Respirology.pdf (495.9 KB) |
| Abstract | Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease (ILD) of unknown aetiology with a median survival of only 2-5 years. It is characterized by progressive dyspnoea and worsening lung function, ultimately resulting in death. Until recently, there were no effective therapies for IPF; however, with the publication of two landmark clinical trials in 2014, the anti-fibrotic therapies, nintedanib and pirfenidone, have gained widespread approval. This position paper aims to highlight the current evidence for the treatment of IPF, with particular application to the Australian and New Zealand population. We also consider areas in which evidence is currently lacking, especially with regard to the broader IPF severity spectrum and treatment of co-morbid conditions. The utility of non-pharmacological therapies including pulmonary rehabilitation, oxygen as well as symptom management thought to be important in the holistic care of IPF patients are also discussed. |
http://www.ibas.org.au/what-we-do/publications/3872987
Interstitial lung disease (ILD) is a chronic lung condition that causes stiff lungs and restricts sufferers from taking a deep breath. Exercise in a gym, such as walking or riding a bike, can help make...
Each year in Australia 260 people sustain a SCI, with over half losing full function in their arms and legs (quadriplegia). In addition to the primary disability, there is a very high rate of Obstructive...
DO YOU HAVE SPINAL CORD INJURY? TIRED? GET TREATED!
Melbourne researchers have found that 80 percent of people with quadriplegic spinal injuries have sleep apnoea. It's having a big effect on their lives but they don't know they have it, and they don't know it can be treated.
WORLD 1ST HEAVY VEHICLE DRIVER FATIGUE STUDY RELEASED
The National Transport Commission (NTC) and the Cooperative Research Centre for Alertness, Safety and Productivity (Alertness CRC) have released the results of what is hailed as a world-first study into heavy vehicle driver fatigue.
AAMRI ELECTION STATEMENT RELEASED ON 25TH MARCH 2019
AAMRI released its election statement calling on politicians to commit to three main priorities: ensuring the MRFF reaches $20 billion by 2020-21, provide continued strong support for the NHMRC, and develop sustainable and rewarding career pathways.
PORTRAIT UNVEILED AT CANBERRA'S PARLIAMENT HOUSE
IBAS Director Anna Burke had barely got into the swing of her speech at the unveiling of her portrait at Canberra's Parliament House when the ringing of bells caused half her audience to hurry away.
© 2020 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
